Management of the toxicities of common targeted therapeutics for gynecologic cancers.

Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Gynecol Oncol. 2018 Jan 30;:
Authors: Gunderson CC, Matulonis U, Moore KN
Abstract
As precision medicine has become a focus in oncology in recent years, many targeted and biologic agents are being used along with or in place of traditional cytotoxic chemotherapy. As these drugs have been developed and some have received FDA approval, we have gained substantial data about the adverse event profiles. However, the management and approach to the toxicities incurred and subsequent complications are often not well understood, especially for physicians who have a varied clinical practice. The purpose of this review is to provide an overview of the frequency and types of adverse events and appropriate management steps when prescribing modern targeted therapies for gynecologic cancers in the classes of anti-angiogenic agents, poly-ADP-ribose polymerase (PARP) inhibitors, and immunotherapy drugs.
PMID: 29395304 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - January 30, 2018 Category: Cancer & Oncology Authors: Gunderson CC, Matulonis U, Moore KN Tags: Gynecol Oncol Source Type: research